This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Zydelig
  • /
  • A Phase 2 Study to Assess the Efficacy and Safety ...
Clinical trial

A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

Read time: 2 mins
Last updated:4th Mar 2011
Identifier: NCT01282424

The purpose of this study is to evaluate the efficacy and safety of idelalisib in patients with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is refractory both to rituximab and to alkylating-agent-containing chemotherapy. The primary objective will be to assess the overall response rate.

Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg taken twice per day. Treatment with idelalisib can continue in compliant patients as long as the study is still ongoing and the patients appear to be benefiting from treatment with acceptable safety.

Category Value
Date last updated at source 2017-04-10
Study type(s) Interventional
Expected enrolment 125
Study start date 2011-03-04
Estimated primary completion date 2017-12-01

View full details